Ciencias de la Salud

URI permanente para esta comunidadhttp://repositorio.uta.edu.ec/handle/123456789/813

Examinar

Resultados de la búsqueda

Mostrando 1 - 2 de 2
  • Item type:Ítem,
    Moduladores de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (cftr) de triple combinación: Revisión bibliográfica
    (2025-10-16)
    Ugsha Toaquiza Lisbeth Mercedes
    ;
    Apolo Loayza Kerly Yuliana, Dra. Esp
    ;
    Universidad Técnica de Ambato / Facultad de Ciencias de la Salud / Carrera de Medicina
    Introduction:Cystic fibrosis is an autosomal recessive genetic disease that affects the function of the CFTR channel. The most common mutation is F508del, found in approximately 90% of patients. CFTR modulators have significantly improved treatment by increasing respiratory function and reducing exacerbations, which impacts survival and quality of life. Materials and Methods:A qualitative systematic review was conducted by searching scientific databases for articles on triple combination CFTR modulators. Relevant studies published in the last 5 years in English and Spanish were included. The selected articles provided information on the efficacy, safety, and adverse effects of the treatments. Results:Cystic fibrosis is caused by mutations in the CFTR gene, primarily affecting the lungs and digestive system. Triple combination modulators such as elexacaftor, tezacaftor, and ivacaftor have shown improvements in lung function and quality of life, especially in patients with common mutations like F508del. Studies also highlight the variability in treatment response, particularly among subgroups of patients with less common mutations. Conclusions:Triple therapy with elexacaftor-tezacaftor-ivacaftor has proven effective in improving lung function and quality of life in patients with cystic fibrosis, especially those with the F508del mutation. The treatment’s safety profile is acceptable, although variations in response among different patient subgroups must be considered.
  • Item type:Ítem,
    EOSINOFILIA, UN BIOMARCADOR DE IMPORTANCIA EN LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA (EPOC).
    (Universidad Técnica de Ambato/ Facultad de Ciencias de Salud /Carrera de Medicina, 2024-06-10)
    Freire Ramos, Erick Alexander
    ;
    Barba Guzmán, Carmen Variña
    Evidence supports that the use of biomarkers to guide COPD treatment is necessary to improve patients' quality of life; However, it does not become an easy task since it brings together different characteristics such as its reliability, its ease of measurement and its relevance within the different EPOC processes. Objective: Determine the importance of eosinophilia as a biomarker in Chronic Obstructive Pulmonary Disease (COPD). Methodology: It is a retrospective descriptive study of a bibliographic nature. An exhaustive search of scientific articles was carried out, such as bibliographic review, cohort and control studies, systematic and bibliographic review, and meta-analysis, in the languages of Spanish and English, using medical information databases; Scielo, Pubmed, Elsevier, Scopus, Google Scholar and Medline. Results: Through the application of inclusion and exclusion criteria, 7 articles have been collected that gather the most relevant information about eosinophilia as a biomarker in Chronic Obstructive Disease. Conclusions: Several authors agree that, although eosinophilia cannot be taken as a reference for diagnosis and determining the severity of COPD symptoms, it can be used to guide treatment and as a predictor of exacerbations in the different stages of the pathology.